Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTCK85E)

DTT Name	Immune costimulatory protein B7H4 (VTCN1)
Synonyms	VTCN1; V-set domain-containing T-cell activation inhibitor 1; T-cell costimulatory molecule B7x; Protein B7S1; B7h.5
Gene Name	VTCN1
DTT Type	Literature-reported target	[1]
BioChemical Class	Immunoglobulin
UniProt ID	VTCN1_HUMAN
TTD ID	T35423
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK
Function	Negatively regulates T-cell-mediated immune response byinhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor- associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation.
KEGG Pathway	Cell adhesion molecules (hsa04514 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD8205	DMXKH0S	Aggressive cancer	2A00-2F9Z	Phase 2	[2]
PF-07260437	DMU7LYP	Breast cancer	2C60-2C65	Phase 1	[3]
------------------------------------------------------------------------------------

References

1	B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look. Gynecol Oncol. 2014 Jul;134(1):181-189.
2	Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clin Cancer Res. 2023 Mar 14;29(6):1086-1101.
3	ClinicalTrials.gov (NCT05067972) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.